



Annual self-assessment against UEBT membership obligations

NOTE:

This document will be made publicly available to stakeholders through the UEBT website

All information should be related to the previous year. Information provided will be part of the next UEBT membership audit

General information	
Name of the company/entity that is member of UEBT	LABORATOIRES EXPANSCIENCE
Web Page	www.expanscience.com
Company Description (Please write a short description of your organisation, its core activities, and its commitment to biodiversity and Ethical BioTrade)	<p>As a 100% family-owned pharmaceuticals and cosmetics laboratory, Expanscience has acknowledged expertise in treating arthritis and in skincare, particularly for babies, teenagers and pregnant women. Placéline 300 and Mustela are now leading brands in France, as well as – increasingly – throughout the rest of the world. How the cutaneous barrier and the human epidermis develop, as well as cartilage, are one of the main areas of expertise on which our centre for research and development is focused.</p> <p>Our core business is people's health and their well-being. In line with these aims, our company has adopted an active corporate social responsibility approach (CSR), factoring in the impact that our business has on people and the environment.</p> <p>At Expanscience, this approach involves a policy whereby we source our raw plant matter supplies in ways that do not harm the farmers and the countries that produce them, and we adopt a more environmentally-friendly approach to our product design. Our research and development involves all our expertise in plant extraction so that we can adopt a safe and well-reasoned approach to developing new active plant ingredients.</p> <p>CSR is one of the things that drives innovation and helps to set us apart. It also helps us strengthen and develop the roles that we play in demo-cosmetics, rheu.</p> <p>Key figures for 2013 : • 2013 turnover: €259,4 million • 92 distributing countries • 12 subsidiaries in Europe and in third-world countries. More information: www</p>
Date of information provided	March 2014

Ethical BioTrade Targets	
Did your organisation set Ethical BioTrade targets? (If no, please specify when the targets will be set.)	<p>Yes</p> <p>The organisation has made an ambitious commitment, totally consistent with the objectives set forth at the time of its adherence to UEBT: by 2015, Expanscience has committed to implement a Corporate Social Responsibility (CSR) action plan on 100% of its own plant supply chains. In 2012, the company had achieved 64% of it; in 2013 the plan, developed from its Innovation, Research and Development Center, was deployed to 20 of its 22 supply chains, or 90%.</p> <p>http://www.expanscience.com/developpement-durable/nos-achats-nos-approvisionnement/nos-actions</p>
How many supply chains has your organisation prioritised? (Fill with numbers only) - prioritised supply chain are those chains in which the Ethical BioTrade standard is implemented in an accelerated way.	22

Implementation of the UEBT Work Plan (WP)	
% of UEBT WP actions that were planned for the last reporting year that have been implemented? (If not all planned actions were implemented, please provide a brief explanation.)	<p>50-75%</p> <p>Expanscience believes that it has implemented the UEBT Work Plan (WP) at 90% of its plant R&D supply chains.</p>

Development of the Biodiversity Management system	
At what stage is the development of the Biodiversity Management System?	Well advanced stage
Over the last year, have you adapted or introduced new internal procedures (e.g. policies, guidelines, questionnaires, audit programmes) to advance on the development of the Biodiversity Management System?	<p>Yes (please describe)</p> <p>Every year, a programme of audits/visits is prepared for industrial-scale sources and those that are planned.</p> <p>In 2013, on a new African project, writing of the specification list and of the partnership agreement making it possible to formalise the prior informed consent form (Access) before working with a prospective plant source.</p> <p>Writing of 6 new identity sheets, covering 20 of the 22 prioritised supply chains.</p> <p>In 2014, Expanscience has committed to writing its general procedure describing its policy for achieving responsible plant sourcing, that respects the challenges of biocommerce.</p>

Implementation of Ethical BioTrade Practices in the Supply Chains

Please describe which activities have been undertaken over the reporting year to advance on the implementation of the Standard and the Ethical BioTrade principles in the supply chains (e.g. producer training; biodiversity conservation projects, suppliers audits, suppliers questionnaires)

Do you have different approaches for prioritised and non prioritised supply chains? If so, please specify.

Expanscience's contribution to Sustainable Development has been recognized as "exemplary" by AFAQ 26000 since September 2013. The organisation is the first dermatology-cosmetics and pharmaceutical laboratory to achieve such a level of exemplarity.

The organisation was also granted the renewal of its ISO 14001 agreement of its industrial site (initially obtained in October 2012).

In 2013, Expanscience wished to go further in its Corporate Social Responsibility (CSR) process, by voluntarily requesting field audits of its avocado supply chains (to obtain the avocado oil used in the composition of PIASCLEDINE 300® mg) and maca (for the production of the cosmetic ingredient Skinergium®) in Peru by an independent third party. Thus, last June, Control Union Peru, a company accredited by UEBT for the conduct of audits according to the Bio Commerce standard, audited these supply chains over 6 days. These audits, a guarantee of transparency and credibility, made it possible to highlight the work performed over the last several years on the field with the partner and the producers. Among the merits found by the UEBT evaluators: transparent supply chains, strong socio-economic impact of the act of purchasing on local development (particularly for avocado), fair and equitable prices, actions to protect the environment.

The organisation communicates actively about its supply chains, with full transparency, on its website:
<http://www.expanscience.com/fr/developpement-durable/nos-achats-nos-approvisionnements/nos-actions>

Expanscience is developing all of its new projects according to the 7 key issues of the Corporate Social Responsibility ISO 26000 standard (governance, environment, social, economic, ethical, human rights, anti-corruption).

The organisation has devoted 36 days to visits/audits of its supply chains and implemented a dozen monetary actions for €55K, for the reinforcement of its local supply chains.

In Peru, a support project against a disease affecting certain avocado trees was launched in order to support farmers. The objective is two-fold: to provide a tree nursery and to train the women in a women's collective on the creation and management of a tree nursery. In the first year, 2000 seedlings were planted.

Also in Burkina Faso, the organisation rehabilitated the multifunctional platform of the collective and built a nursery for children from 2 to 5 years of age, allowing them to attend school.

In Mexico, supply of personal protection equipment (PPE) for employees of the unit for extraction of avocado oil, as well as foodstuffs and family pharmacies.

In Peru and Burkina Faso, Expanscience engaged true governmental action with the relevant authorities on the focus of ABS and the Nagoya Protocol for access and benefit sharing.

Writing of an additional ethnobotany report in Peru on a prospective plant.

In 2013, the organisation performed a Life Cycle Analysis (LCA) on its drug PIASCLEDINE 300® mg, subject to a specific plan aiming to measure its impact on the environment.

Finally, as soon as it is feasible, Expanscience encourages and helps its partners to develop other sources of revenue, even outside of trade purposes between them.

Additional Information

Please provide additional information, if any, that might be relevant to report in the context of UEBT membership. For example, issues related to Access and Benefit Sharing, new partnership(s), additional certifications, etc.

In 2013, 4.3% of its sales invested in Research and Development (affiliates, green processes, products, innovation).

In 2013, Expanscience had the distinction of various awards related to Sustainable Development:

- CCI Eure-et-Loir, Trophies of Performance, category "Sustainable Development": Laboratoires Expanscience, winner
 - Cosmetic Valley: for an "eco-responsible" Cosmetic Valley: Laboratoires Expanscience, "4 peonies"
 - Sustainable Beauty awards, category "Sustainable Packaging": Mustela brand, winner.
 - Business and Environment Prize: category of "biodiversity" of the Ministry: Laboratoires Expanscience, nominated
- Participation in the 4th International Forum Africa and Beauty, presentations and contribution to the theme ABS/Nagoya Protocol (experience in the field)

Documents annexed for public use?

No